pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
8951-CL-5201
Phase 2 · small molecule · First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
8951-CL-5201 for First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. is a Phase 2 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code 8951-CL-5201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astellas Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
- Status
- active
- Trials
- 1